Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 41 to 50 of 75

TitleReference numberPublishedLast updated
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536

Results per page

  1. 10
  2. 25
  3. 50
  4. All